The discussion highlights the potential of peptide therapy, particularly thymus-derived peptides like thymosin beta four and thymulin, in treating neuropathies, including those related to COVID-19. While ozone therapy and hyperbaric oxygen show mixed results, peptides are gaining attention for their natural healing properties. ARA 290 emerges as a promising FDA-approved option, despite its limited availability and high cost.
